THU0408 How we are Treating Our Systemic Patients with Primary Sjögren Syndrome? Analysis of 1120 Patients (GEAS-SS Spanish Registry)
| Autor: | R. Qanneta, Soledad Retamozo, L. Morera-Morales, Roberto Pérez-Alvarez, A. Casanovas, P. Brito Zeron, J. Nava-Mateos, Manuel Ramos-Casals, H. Gheitasi, Blanca Pinilla, Xavier Bosch, M. Ripoll, M. Akasbi, R. Solans, B. Kostov, B. Díaz-Lόpez, C. Suárez-Cuervo, F.-J. Rascόn, Guadalupe Fraile |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
medicine.medical_specialty Systemic disease Anemia business.industry media_common.quotation_subject Immunology Chronic pain Hydroxychloroquine medicine.disease General Biochemistry Genetics and Molecular Biology Rheumatology Refractory Internal medicine Cohort medicine Immunology and Allergy Rituximab business medicine.drug media_common |
| Zdroj: | Annals of the Rheumatic Diseases. 74:344.2-344 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2015-eular.3363 |
| Popis: | Objectives To describe how systemic disease is treated in a large cohort of Spanish patients with primary Sjogren syndrome in daily practice, focusing on the adequacy of drug therapies for the level of systemic activity measured by the ESSDAI score. Methods By December 2014, our database included 1120 consecutive patients who fulfilled the 2002 classification criteria for primary SS. Therapeutic schedules were classified into 4 categories: no systemic therapies, hydroxychloroquine and/or low dose of glucocorticoids (≤20 mg/d), high dose of glucocorticoids (>20 mg/d) and use of second-line therapies (immunosuppressive agents, intravenous immunoglobulins and/or rituximab). Results The cohort consisted of 1120 patients, including 1048 (94%) females and 72 (6%) males, with a mean age at diagnosis of 54 years. The main drug-based therapeutic approaches for systemic Sjogren ever used during the follow-up were hydroxychloroquine (HCQ) in 282 (25%) patients, glucocorticoids in 475 (42%, used at doses >20 mg/d in 255 -23%>), immunosuppressive agents in 148 (13%), intravenous immunoglobulins (IVIG) in 25 (2%) and rituximab in 35 (3%) patients. The use of systemic therapies was more frequent in males (p=0.036) and was associated with the presence at diagnosis of anemia (p 20 mg of corticoids and 21/148 (14%) of those treated with immunosuppressive agents patients as inadequately treated, mainly associated with articular involvement of low/moderate activity. Conclusions The management of systemic Sjogren should be organ-specific, using low doses of corticoids in patients with moderate systemic activity, limiting the use of high doses of corticoids and second-line therapies to refractory or potentially-severe scenarios. The use of systemic therapies for dryness, chronic pain or fatigue is not warranted. Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|